Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ahmed, 2005, Advanced glycation endproducts—role in pathology of diabetic complications, Diabetes Res. Clin. Pract., 67, 3, 10.1016/j.diabres.2004.09.004
Maillard, 1912, Action des acides aminés sur les sucres: formation des mélanoïdes par voie méthodique, C. R. Acad. Sci., 154, 66
Bunn, 1981, Reaction of monosaccharides with proteins: possible evolutionary significance, Science, 213, 222, 10.1126/science.12192669
Monnier, 2003, Intervention against the Maillard reaction in vivo, Arch. Biochem. Biophys., 419, 1, 10.1016/j.abb.2003.08.014
Monnier, 2005, Cross-linking of the extracellular matrix by the Maillard reaction in aging and diabetes: an update on “a puzzle nearing resolution”, Ann. N. Y. Acad. Sci., 1043, 533, 10.1196/annals.1333.061
Sternberg, 1995, Effects of the glycation process on the macromolecular structure of the glomerular basement membranes and on the glomerular function in aging and diabetes, C. R. Soc. Biol., 189, 967
Brownlee, 2001, Biochemistry and molecular biology of diabetic complications, Nature, 414, 813, 10.1038/414813a
Jerums, 2003, Evolving concepts in advanced glycation, diabetic nephropathy and diabetic vascular disease, Arch. Biochem. Biophys., 419, 55, 10.1016/j.abb.2003.08.017
Vlassara, 2005, Advanced glycation in health and disease; role of the modern environment, Ann. N. Y. Acad. Sci., 1043, 452, 10.1196/annals.1333.051
Brownlee, 1986, Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking, Science, 232, 1629, 10.1126/science.3487117
Thornalley, 2000, Kinetics and mechanism of the reaction of aminoguanidine with alpha-oxaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions, Biochem. Pharmacol., 60, 55, 10.1016/S0006-2952(00)00287-2
Thornalley, 2003, Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts, Arch. Biochem. Biophys., 419, 31, 10.1016/j.abb.2003.08.013
Khatami, 1988, Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylation, Life Sci., 43, 1725, 10.1016/0024-3205(88)90484-5
Lewis, 1990, The effects of aminoguanidine on the glycation (non-enzymatic glycolation) of lens proteins, Exp. Eye Res., 50, 463, 10.1016/0014-4835(90)90033-Q
Corbett, 1992, Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction, Diabetes, 41, 552, 10.2337/diabetes.41.4.552
Lo, 1994, The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins, Biochem. Pharmacol., 48, 1865, 10.1016/0006-2952(94)90584-3
Yu, 1997, Aminoguanidine inhibits semicarbazide-sensitive oxidase activity: implications for advanced glycation and diabetic complications, Diabetologia, 40, 1243, 10.1007/s001250050816
Giardino, 1998, Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis, Diabetes, 47, 1114, 10.2337/diabetes.47.7.1114
Ihm, 1999, Effect of aminogaunidine on lipid peroxidation in streptozotocin-induced diabetic rats, Metabolism, 48, 1141, 10.1016/S0026-0495(99)90128-2
Price, 2001, Chelating activity of advanced glycation end-product inhibitors, J. Biol. Chem., 276, 48967, 10.1074/jbc.M108196200
Soulis, 1996, Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment, Kidney Int., 50, 627, 10.1038/ki.1996.358
Forbes, 2001, Renoprotective effects of a novel inhibitor of advanced glycation, Diabetologia, 44, 108, 10.1007/s001250051587
Kelly, 2001, Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy, J. Am. Soc. Nephrol., 12, 2098, 10.1681/ASN.V12102098
Sigimoto, 1999, Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminogaunidine ameliorates the overexpression of tumor necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli, Diabetologia, 42, 878, 10.1007/s001250051241
Soulis, 1997, Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats, Diabetologia, 40, 1141, 10.1007/s001250050799
Osicka, 2001, Aminoguanidine and ramipril prevents diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery, Clin. Sci., 100, 249, 10.1042/CS20000194
Birell, 2002, The effects of aminoguanidine on renal changes in a baboon model of type I diabetes, J. Diabetes Complications, 16, 301, 10.1016/S1056-8727(01)00225-2
Yamauchi, 1997, Effects of aminoguanidine on serum advanced glycation endproducts, urinary albumin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats, Diabetes Res. Clin. Pract., 34, 127, 10.1016/S0168-8227(96)01339-3
Hammes, 1991, Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy, Proc. Natl. Acad. Sci. USA, 88, 11555, 10.1073/pnas.88.24.11555
Hammes, 1995, Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats, Diabetologia, 38, 269, 10.1007/BF00400629
Roufail, 1998, Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine, Diabetologia, 41, 1419, 10.1007/s001250051087
Kern, 2000, Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia, Invest. Ophtamol. Vis. Sci., 41, 3972
Kern, 2001, Pharmacological inhibition of diabetic retinopathy. Aminoguanidine and aspirin, Diabetes, 50, 1336, 10.2337/diabetes.50.7.1636
Kihara, 1991, Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals, Proc. Natl. Acad. Sci. USA, 88, 6107, 10.1073/pnas.88.14.6107
Yagihashi, 1992, Effects of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats, Diabetes, 41, 47, 10.2337/diabetes.41.1.47
Miyauchi, 1996, Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozotocin-induced diabetic rats, Eurp. J. Endocrinol., 134, 467, 10.1530/eje.0.1340467
Cameron, 1996, Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: modulation by nitric oxide synthase inhibition, Metabolism, 45, 1147, 10.1016/S0026-0495(96)90015-3
Schmidt, 1996, Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic ganglia of rats with streptozotocin-induced diabetes, Diabetes, 45, 284, 10.2337/diabetes.45.3.284
Birell, 2000, Functional and structural abnormalities in the nerves of type I diabetic baboons: aminoguanidine treatment does not improve nerve function, Diabetologia, 43, 110, 10.1007/s001250050014
Vlassara, 1992, Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications, Proc. Natl. Acad. Sci. USA, 89, 12043, 10.1073/pnas.89.24.12043
Li, 1996, Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine, Proc. Natl. Acad. Sci. USA, 93, 3902, 10.1073/pnas.93.9.3902
Corman, 1998, Amonoguanidine prevents age-related stiffening and cardiac hypertrophy, Proc. Natl. Acad. Sci. USA, 95, 1301, 10.1073/pnas.95.3.1301
Sell, 2001, Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fisher 344 rat. J Gerontol A. Sci, Med. Sci. (Paris), 56, 405
Bolton, 2004, Randomized trial of an inhibitor of formation of advanced glycation and products in diabetic nephropathy, Am. J. Nephrol., 24, 32, 10.1159/000075627
Freedman, 1999, Design and baseline characteristics for the aminoguanidine clinical trial in overt type II diabetic nephropathy (ACTION II), Control. Clin. Trials, 20, 493, 10.1016/S0197-2456(99)00024-0
Miyata, 1998, Accumulation of carbonyls accelerates the formation of pentosidine, advanced glycation end product: carbonyl stress in uremia, J.Am. Soc. Nephrol., 9, 2349, 10.1681/ASN.V9122349
Miyata, 2000, Mechanism of the inhibitory effect of OPB-9195 [(+)-2-isopropylidenehydrazono-4-oxo-thizolidin-5-ylacetanilide] on advanced glycation end product and advanced lipoxidation end product formation, J. Am. Soc. Nephrol., 11, 1719, 10.1681/ASN.V1191719
Nakamura, 1997, Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation, Diabetes, 46, 895, 10.2337/diabetes.46.5.895
Tsuchida, 1999, Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195, Diabetologia, 42, 579, 10.1007/s001250051198
Yamamoto, 2001, Development and prevention of advanced diabetic nephropathy in RAGE-over expressing mice, J. Clin. Invest., 108, 261, 10.1172/JCI11771
Wada, 2001, Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy, Eur. J. Clin. Invest., 31, 513, 10.1046/j.1365-2362.2001.00826.x
Yatoh, 2006, Antioxidant and an inhibitor of advanced glycation ameliorate death of retinal microvascular cells in diabetic retinopathy, Diabetes Metab. Res. Rev., 22, 38, 10.1002/dmrr.562
Miyata, 2005, From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy, Ann. N. Y. Acad. Sci., 1043, 740, 10.1196/annals.1333.086
Rahbar, 2003, Novel inhibitors of advanced glycation endproducts, Arch. Biochem. Biophys., 419, 63, 10.1016/j.abb.2003.08.009
Figarola, 2003, LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats, Diabetologia, 46, 140
Figarola, 2005, Prevention of early renal disease, dyslipidemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74 novel AGE inhibitors, Diabetes Metab. Res. Rev., 21, 533, 10.1002/dmrr.550
Booth, 1997, In vitro kinetics studies of formation of antigenic advanced glycation end products (AGEs), J. Biol. Chem., 272, 5387, 10.1074/jbc.272.9.5430
Voziyan, 2003, Modification of proteins in vitro by physiological levels of glucose, J. Biol. Chem., 278, 46616, 10.1074/jbc.M307155200
Onorato, 2000, Pyrodoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions, J. Biol. Chem., 275, 21177, 10.1074/jbc.M003263200
Voziyan, 2002, A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation, J. Biol. Chem., 277, 3397, 10.1074/jbc.M109935200
Metz, 2003, Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications, Arch. Biochem. Biophys., 419, 41, 10.1016/j.abb.2003.08.021
Degenhard, 2002, Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat, Kidney Int., 61, 939, 10.1046/j.1523-1755.2002.00207.x
Stitt, 2002, The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes, Diabetes, 51, 2826, 10.2337/diabetes.51.9.2826
Alderson, 2003, The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats, Kidney Int., 63, 2123, 10.1046/j.1523-1755.2003.00027.x
Berrone, 2006, Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose, J. Biol. Chem., 281, 9307, 10.1074/jbc.M600418200
Hammes, 2003, Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy, Nat. Med., 9, 294, 10.1038/nm834
Stracke, 2001, Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats, Exp. Clin. Endocrinol. Diabetes, 109, 330, 10.1055/s-2001-17399
Babei-jadidi, 2003, Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine, Diabetes, 52, 2120
Gadau, 2006, Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis, Diabetologia, 49, 405, 10.1007/s00125-005-0103-5
Vasan, 1996, An agent cleaving glucose-derived protein crosslinks in vitro and in vivo, Nature, 382, 211, 10.1038/382275a0
Cooper, 2000, The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation, Diabetologia, 45, 600
Oturai, 2000, Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats, Metabolism, 49, 996, 10.1053/meta.2000.7731
Yang, 2003, AGE-breakers cleave model compounds but not break Maillard crosslinks in skin and tail collagen from diabetic rats, Arch. Biochem. Biophys., 412, 42, 10.1016/S0003-9861(03)00015-8
Thornalley, 1999, Rapid hydrolysis and slow alpha, beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links, Biochem. Pharmacol., 57, 303, 10.1016/S0006-2952(98)00284-6
Mentink, 2002, Glucose-mediated cross-linking of collagen in rat tendon and skin, Clin. Chim. Acta, 32, 69, 10.1016/S0009-8981(02)00097-9
Wolffenbuttel, 1998, Breakers of advanced glycation end products restore large artery properties in experimental diabetes, Proc. Natl. Acad. Sci. USA, 95, 4630, 10.1073/pnas.95.8.4630
Asif, 2000, An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness, Proc. Natl. Acad. Sci. USA, 97, 2809, 10.1073/pnas.040558497
Vaitkevicius, 2001, A cross-link breaker has sustained effect on arterial and ventricular properties in older rhesus monkey, Proc. Natl. Acad. Sci. USA, 98, 1171, 10.1073/pnas.98.3.1171
Liu, 2003, Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart, Am. J. Physiol., 285, H2587
Susic, 2004, Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats, Am. J. Hypertens., 17, 328, 10.1016/j.amjhyper.2003.12.015
Forbes, 2003, The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes, FASEB J., 17, 1762, 10.1096/fj.02-1102fje
Thallas-Bonke, 2004, Attenuation of extracellular matrix accumulation in diabetic nephropathy by advanced glycation end product cross-link breaker ALT 711 via a protein kinase C-α-dependant pathway, Diabetes, 53, 2921, 10.2337/diabetes.53.11.2921
Lassila, 2004, Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end products, J. Am. Soc. Nephrol., 15, 2125, 10.1097/01.ASN.0000133025.23732.46
Forbes, 2004, Advanced glycation end product intervention reduce diabetes-accelerated atherosclerosis, Diabetes, 53, 1813, 10.2337/diabetes.53.7.1813
Vasan, 2003, Therapeutic potential odd breakers of advanced glycation end product-protein cross links, Arch. Biochem. Biophys., 419, 89, 10.1016/j.abb.2003.08.016
Little, 2005, The effect of alagebrium chloride (ALT 711), a novel glucose crosslink breaker, in treatment of elderly patients with diastolic heart failure, J. Card. Fail., 11, 191, 10.1016/j.cardfail.2004.09.010
Kim, 2005, Receptor for advanced glycation end products and its ligands, Ann. N. Y. Acad. Sci., 1043, 553, 10.1196/annals.1338.063
Wendt, 2003, RAGE drives the development of glomeruloslerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy, Am. J. Pathol., 162, 1123, 10.1016/S0002-9440(10)63909-0
Kislinger, 2001, Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice, Arterioscler. Thromb. Vasc. Biol., 21, 905, 10.1161/01.ATV.21.6.905
Bucciarelli, 2002, RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice, Circulation, 106, 2827, 10.1161/01.CIR.0000039325.03698.36
Goova, 2001, Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice, Am. J. Pathol., 159, 513, 10.1016/S0002-9440(10)61723-3
Yonekura, 2003, Novel splice variants of the receptor for advanced end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury, Biochem. J., 370, 1097, 10.1042/bj20021371
Geroldi, 2005, Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension, J. Hypertens., 23, 1725, 10.1097/01.hjh.0000177535.45785.64
Pullerits, 2005, Decreased levels of soluble receptor for advanced end products in patients with rheumatoid arthritis indicating deficient inflammatory control, Arthritis Res. Thr., 7, R817, 10.1186/ar1749
Kalousova, 2006, Soluble receptor for advanced glycation end products in patients with decreased renal function, Am. J. Kidney Dis., 47, 406, 10.1053/j.ajkd.2005.12.028
Zheng, 2001, Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppress adverse age-mediated cellular effects in vitro: a potential AGE sequestration therapy for diabetes nephropathy, Mol. Med., 7, 737, 10.1007/BF03401963
Flyvberg, 2004, Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice, Diabetes, 53, 16672
Jensen, 2006, Renal effects of a neutralizing Rage-antibody in long-term streptozotocin-diabetic mice, J. Endocrinol., 188, 493, 10.1677/joe.1.06524
Okamoto, 2002, Angiogenesis induced by advanced glycationn end products and its prevention by cerivastatin, FASEB J., 16, 1928, 10.1096/fj.02-0030fje
Ruggiero-Lopez, 1999, Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation, Biochem. Pharmacol., 58, 1765, 10.1016/S0006-2952(99)00263-4
Kito, 2005, Effect of butformin and metformin on formation of advanced glycation end products by methyl glyoxal, Clin. Chim. Acta, 358, 139, 10.1016/j.cccn.2005.02.012
Tanaka, 1999, Effect of metformin on advanced glycaton endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats, Europ. J. Pharmacol., 376, 17, 10.1016/S0014-2999(99)00342-8
Beisswenger, 1999, Maillard Reactions in chemistry food and health, Cambridge: The Royal Society of chemistry, 48, 198
Rahbar, 2000, Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation, Clin. Chem. Acta, 301, 65, 10.1016/S0009-8981(00)00327-2
Tanimoto, 2004, Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice, Metabolism, 53, 1473, 10.1016/j.metabol.2004.06.016
Allen, 1997, Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies, Diabetes, 46, 11612, 10.2337/diabetes.46.10.1612
Miyata, 2002, Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms, J. Am. Soc. Nephrol., 13, 2478, 10.1097/01.ASN.0000032418.67267.F2
Forbes, 2002, Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy, Diabetes, 51, 3274, 10.2337/diabetes.51.11.3274
Forbes, 2004, The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes, Kidney Int. Suppl., 92, S105, 10.1111/j.1523-1755.2004.09225.x
Yamagishi, 2005, Olmesartan medoxomil, a newly developed angiotensin II type I receptor antagonist, protect against renal damage in advanced glycation end product (age)-injected rats, Drugs Exp. Clin. Res., 31, 45
Osicka, 2000, Prevention of albuminuria by aminoguanidine or ramipril in streptopzotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C, Diabetes, 49, 87, 10.2337/diabetes.49.1.87
Davis, 2004, Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the spontaneously hypertensive rats, Diabetologia, 47, 89, 10.1007/s00125-003-1256-8
Forbes, 2005, Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy, J. Am. Soc. Nephrol., 16, 2363, 10.1681/ASN.2005010062
Fan, 2004, Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice, Nephrol. Dial. Transplant., 19, 3012, 10.1093/ndt/gfh499
Wihler, 2005, Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition, Diabetologia, 48, 1645, 10.1007/s00125-005-1837-9
Jandelait-Dahm, 2005, Anti-atherosclerotic and renoprotective effect of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice, J. Hypertens., 23, 2071, 10.1097/01.hjh.0000184747.41565.a1
Dan, 2004, Interaction between the polyol pathway and non-enzymatic glycation on aortic smooth muscle cell migration and monocyte adhesion, Life Sci., 70, 445, 10.1016/j.lfs.2004.09.010
Suarez, 1988, Administration of an aldose reductase inhibitor induces a decrease of collagen fluorescence in diabetic rats, J. Clin. Invest., 82, 624, 10.1172/JCI113641
Cohen, 1991, Evaluation of the effect of aldose reductase inhibition on increased basement membrane collagen fluorescence in diabetic rats, Gen. Pharmacol., 22, 603, 10.1016/0306-3623(91)90063-C
Soulis-Liporata, 1995, The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague–Dawley rat, Diabetologia, 38, 387, 10.1007/BF00410275
Engerman, 1994, Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosemic dogs, Diabetologia, 37, 141, 10.1007/s001250050084
Kern, 1999, Aldose reductase and the development of renal disease in diabetic dogs, J. Diabetes Complications, 13, 10, 10.1016/S1056-8727(98)00015-4
Hamada, 2000, Epalrestat, an aldose reductase inhibitor, reduces the levels of N-(carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients, Diabetes Care, 23, 1539, 10.2337/diacare.23.10.1539
Ou, 1996, Activation of aldose reductase in rat lens and metal-ion chelalation by aldose reductase inhibitors and lipoic acid, Free Radic. Res., 25, 337, 10.3109/10715769609149056
Nakamura, 2003, Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2, Diabetes In Vivo, 17, 177
Blakytny, 1992, Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen, Exp. Eye Res., 54, 509, 10.1016/0014-4835(92)90129-G
Cotlier, 1981, Aspirin effect on cataract formation in patients with rheumatoid arthritis alone or combined with diabetes, Int. Ophtalmol., 3, 173, 10.1007/BF00130701
Yue, 1984, The effect of salicylates on nonenzymatic glycosylation and thermal stability of collagen in diabetic rats, Diabetes, 33, 745, 10.2337/diabetes.33.8.745
Fu, 1994, Effects of aspirin on glycation, glycoxidation, and cross-linking of collagen, 95
Urios, 2005, Aspirin inhibits pentosidine formation in collagen incubated with glucose, Ann. N. Y. Acad. Sci., 1043, 941, 10.1196/annals.1333.155
Dinis, 1994, Action of phenolic derivatives (acetaminophen, salicylates) as inhibitors of lipid membrane lipid peroxidation and as peroxyl radicals scavengers, Arch. Biochem. Biophys., 315, 161, 10.1006/abbi.1994.1485
Contreras, 1997, Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM, Diabetes Care, 20, 832, 10.2337/diacare.20.5.832
Van Boekel, 1992, Glycation of human serum albumin: inhibition by diclofenac, Biochim. Biophys. Acta, 1120, 201, 10.1016/0167-4838(92)90270-N
Cohen, 2000, Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse, Exp. Nephrol., 8, 135, 10.1159/000020661
Shoda, 1997, Inhibitory effects of tenilsetam on the Maillard reaction, Endocrinology, 138, 1886, 10.1210/en.138.5.1886
Giardino, 1995, Vitamin E prevents diabetes-induced formation of arterial wall intracellular advanced glycation endproducts, Diabetes, 44, 73A
Ceriello, 2003, New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy, Diabetes Care, 26, 1589, 10.2337/diacare.26.5.1589
Saxena, 2000, Transition metal-catalyzed oxidation of ascorbate in human cataract extracts: possible role of advanced glycation endproducts, Invest. Ophtalmol., 41, 1473
Sternberg, 2002, Compared inhibition of pentosidine formation in type-I collagen incubated with glucose by catechin, myricetin, kaempferol and quercetin: role of flavonoid structure, Diabetologia, 45, A393
Odetti, 1990, Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin, Diabetes, 39, 796, 10.2337/diabetes.39.7.796
Urios, 2000, Long-term treatment with a purified micronized flavonoid fraction reduces urinary albumin clearance and restores albuminemia in normotensive and hypertensive diabetic rats, Diabetes Res. Clin. Pract., 50, S362